Guancial Elizabeth A, Chowdhury Dipanjan, Rosenberg Jonathan E
Clinical Fellow in Hematology and Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA 02115, 617-632-3779 (telephone), 617-632-5822 (fax),
Clin Investig (Lond). 2011 Apr;1(4):546-555. doi: 10.4155/cli.11.26.
Despite a detailed understanding of the molecular aberrations driving the development of urothelial cancers, this knowledge has not translated into advances for the treatment of this disease. Urothelial cancers are chemosensitive, and platinum-based combination chemotherapy remains the standard of care for advanced disease, as well as neoadjuvant and adjuvant therapy for locally advanced disease. However, nearly half of patients who undergo resection of locally advanced urothelial cancer will relapse and eventually develop platinum-resistant disease. Clinical trials of targeted agents against angiogenesis and growth factors, as well as novel chemotheraputics, have generally been unsuccessful in urothelial cancers. Improvements in the theraputic arsenal for urothelial cancer depend upon identification of new targets and strategies to overcome platinum resistance.
尽管对驱动尿路上皮癌发展的分子畸变有了详细了解，但这一知识尚未转化为该疾病治疗方面的进展。尿路上皮癌对化疗敏感，基于铂的联合化疗仍然是晚期疾病以及局部晚期疾病新辅助和辅助治疗的标准治疗方法。然而，近一半接受局部晚期尿路上皮癌切除术的患者会复发，并最终发展为铂耐药疾病。针对血管生成和生长因子的靶向药物以及新型化疗药物的临床试验在尿路上皮癌中通常未取得成功。尿路上皮癌治疗手段的改进取决于新靶点的识别以及克服铂耐药的策略。
